View Post

Savvy Cooperative Opportunity: Share Your Expertise as an Acute Myeloid Leukemia (AML) patient

In In The News by Barbara Jacoby

Click on the link below to see whether you qualify: Interview: Share your thoughts on living with Acute Myeloid Leukemia (AML) (Anywhere) – $125 Description: We are working on a new project and we are hoping to speak with Acute Myeloid Leukemia (AML) patients and hear about your experience living with the condition and thoughts about your current treatment regimen. …

View Post

Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory AML or Higher Risk MDS

In Clinical Trials by Barbara Jacoby

From: prnewswire.com – Milestone represents the first patient dosed with Precigen’s transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the …

View Post

BioTheryX Announces FDA approval of IND Application to Initiate Phase I Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia

In Clinical Trials by Barbara Jacoby

Expects Enrollment of Phase I Trial to Begin in the Third Quarter of 2019 BioTheryX, Inc. (“BioTheryX”), a biotechnology company creating new classes of drugs based on multi-kinase inhibition and targeted protein degradation, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared BioTheryX’s investigational new drug application (“IND”) for BTX-A51, an oral multi-kinase inhibitor, for the treatment …

View Post

EARLY CANCER DEATHS LINKED TO BEING SINGLE, LIVING IN A POOR NEIGHBORHOOD

In In The News by Barbara Jacoby

Patients in California hospitals were more likely to die within 60 days of being diagnosed with acute myeloid leukemia – a cancer of the blood and bone marrow – if they were unmarried, lived in a less-affluent neighborhood or lacked health insurance. The UC Davis study also found that patients treated at a National Cancer Institute (NCI)-designated cancer center were …

View Post

Lehi biotech company developing cancer treatment drug

In In The News by Barbara Jacoby

By: Jason Lee From: deseretnews.com David Bearss doesn’t remember his grandfather. The family patriarch was in his 40s when he was diagnosed with colon cancer in 1969 — the year Bearss was born. He died before Bearss was old enough to know him. “I have pictures of him holding me as a baby,” Bearss said. “But with cancer in those …

View Post

Biopharmaceutical Company Granted Orphan Designation from the European Medicines Agency

In In The News by Barbara Jacoby

Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B – Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained. – Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016. – Iomab-B now has orphan designation in the …

Wow. Agios’ Experimental Leukemia Drug Makes Cancer Undetectable In Three Patients

In In The News by Barbara Jacoby

By: Matthew Harper From: Forbes.com Agios, a biotechnology company based in Cambridge, Mass., has seemed in some ways a sign of the overexcitement of the recent biotech boom. After all, the company, despite an experienced management team, a July public stock offering that raised more than $100 million, and great scientific ideas, hasn’t been able to show a single result …